MONITORING MANTLE CELL LYMPHOMA CLONOTYPES IN PERIPHERAL BLOOD AFTER IMMUNOTRANSPLANT
The invention is directed to a method of monitoring a mantle cell lymphoma residual disease in an immunotransplant patient by post-treatment analysis of clonotype profiles from patient blood samples. In some embodiments, methods of the invention comprising steps of (a) treating a patient by immunotransplanting the patient with vaccine-primed autologous T cells; (b) obtaining a peripheral blood sample from the patient comprising B-cells and/or cell-free nucleic acids; (c) amplifying molecules of nucleic acid from the B-cells of the sample and/or cell-free nucleic acids in the sample, the molecules of nucleic acid comprising recombined DNA sequences from immunoglobulin genes; (d) sequencing the amplified molecules of nucleic acid to form a clonotype profile; and (e) determining from the clonotype profile a presence, absence and/or level of the one or more patient-specific clonotypes correlated with the mantle cell lymphoma, including phylogenic clonotypes thereof.
1 . A method of monitoring a mantle cell lymphoma residual disease in a patient by one or more patient-specific clonotypes correlated with the mantle cell lymphoma, the method comprising the steps of:
(a) treating a patient by immunotransplanting the patient with vaccine-primed autologous T cells;
(b) obtaining a peripheral blood sample from the patient comprising B-cells and/or cell-free nucleic acids;
(c) amplifying molecules of nucleic acid from the B-cells of the sample and/or cell-free nucleic acids in the sample, the molecules of nucleic acid comprising recombined DNA sequences from immunoglobulin genes;
(d) sequencing the amplified molecules of nucleic acid to form a clonotype profile; and
(e) determining from the clonotype profile a presence, absence and/or level of the one or more patient-specific clonotypes correlated with the mantle cell lymphoma, including phylogenic clonotypes thereof.
2 . The method of claim 1 further including the step of repeating said steps (b) through (e) to monitor said mantle cell lymphoma residual disease in the patient.
3 . The method of claim 1 wherein each of said clonotype profiles includes every clonotype present at a frequency of 0.01 percent or greater with a probability of ninety-nine percent.
4 . The method of claim 1 wherein each of said clonotype profiles includes at least 10 4 clonotypes.
5 . The method of claim 1 wherein said one or more patient-specific clonotypes correlated with said mantle cell lymphoma are determined from a bone marrow sample or a lymph node sample of the patient.
6 . A method of monitoring a mantle cell lymphoma in a patient by one or more patient-specific clonotypes correlated with the mantle cell lymphoma, the method comprising the steps of:
(a) treating a patient by immunotransplanting the patient with vaccine-primed autologous T cells;
(b) obtaining a peripheral blood sample from the patient comprising B-cells, plasma cells and/or cell-free nucleic acids from B-cells and/or plasma cells;
(c) extracting a nucleic acid sample from the peripheral blood sample;
(d) amplifying in a polymerase chain reaction molecules of nucleic acid from nucleic acid sample, the molecules of nucleic acid comprising a VDJ rearrangement of IgH;
(e) sequencing the amplified molecules of nucleic acid to form a clonotype profile; and
(f) determining from the clonotype profile a level of each of the one or more patient-specific clonotypes correlated with the mantle cell lymphoma, wherein such levels include phylogenic clonotypes of each of such one or more patient-specific clonotypes.
7 . The method of claim 6 wherein said step of sequencing includes generating sequence reads in a range of from 20 to 400 nucleotides for determining a sequence of each clonotype.
8 . The method of claim 6 wherein said step of determining includes correlating a decreased likelihood of remission with said level of said one or more patient-specific clonotypes correlated with said mantle cell lymphoma.